Table 1 |
||||
|
Effect of estriol on mammary carcinogenesis |
||||
| Treatment |
Duration |
Mammary cancer incidence |
Rats with mammary cancer (%) |
Average number of cancers per rat |
|
|
||||
| Control |
3 weeks |
8/10 |
80 |
1.7 ± 0.4 |
| 30 mg estriol |
1 week |
10/12 |
83 |
1.6 ± 0.3 |
| 200 μg estriol |
1 week |
11/11 |
100 |
1.7 ± 0.3 |
| 30 mg estriol + 30 mg progesterone |
1 week |
7/12 |
58 |
1.2 ± 0.3 |
| 200 μg estriol + 30 mg progesterone |
1 week |
9/12 |
75 |
1.6 ± 0.3 |
| 30 mg estriol |
3 weeks |
7/11 |
64 |
1.0 ± 0.3 |
| 200 μg estriol |
3 weeks |
9/12 |
75 |
1.6 ± 0.3 |
| 30 mg estriol + 30 mg progesterone |
3 weeks |
3/12* |
25 |
0.4 ± 0.2* |
| 200 μg estriol + 30 mg progesterone |
3 weeks |
9/11 |
82 |
2.0 ± 0.4 |
|
|
||||
|
Rats were treated with N-methyl-N-nitrosourea at 7 weeks of age. At 9 weeks of age, the rats were treated with hormones for 1 or 3 weeks. Control rats received empty silastic capsules. *P < 0.05 compared with controls. |
||||
|
Rajkumar et al. Breast Cancer Res 2004 6:R31 doi:10.1186/bcr734 |
||||
